Nuvalent (NASDAQ:NUVL) CEO James Richard Porter Sells 30,000 Shares

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 30,000 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $88.53, for a total transaction of $2,655,900.00. Following the transaction, the chief executive officer owned 324,879 shares of the company’s stock, valued at approximately $28,761,537.87. The trade was a 8.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

James Richard Porter also recently made the following trade(s):

• On Monday, May 4th, James Richard Porter sold 30,000 shares of Nuvalent stock. The shares were sold at an average price of $101.69, for a total transaction of $3,050,700.00.
• On Monday, April 6th, James Richard Porter sold 30,000 shares of Nuvalent stock. The shares were sold at an average price of $103.77, for a total transaction of $3,113,100.00.

Nuvalent Stock Performance

NUVL opened at $123.35 on Thursday. The firm has a market cap of $9.74 billion, a P/E ratio of -20.35 and a beta of 1.15. The firm has a 50-day moving average of $103.44 and a 200 day moving average of $103.19. Nuvalent, Inc. has a fifty-two week low of $71.13 and a fifty-two week high of $123.62.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the prior year, the company posted ($1.18) EPS. Equities research analysts predict that Nuvalent, Inc. will post -5.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on NUVL shares. Robert W. Baird set a $122.85 target price on shares of Nuvalent in a research report on Tuesday. Cantor Fitzgerald lowered shares of Nuvalent from an “overweight” rating to a “neutral” rating in a research report on Tuesday. Stifel Nicolaus set a $124.00 target price on shares of Nuvalent in a research report on Tuesday. TD Cowen lowered shares of Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 target price for the company. in a research report on Tuesday. Finally, HC Wainwright lowered shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 target price for the company. in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $131.15.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s all-cash acquisition offer values Nuvalent at roughly $10.6 billion and implies a meaningful premium to recent trading levels, giving shareholders a clear exit price. Reuters article on GSK deal
• Positive Sentiment: Analysts and market commentary suggest the deal makes strategic sense for GSK because Nuvalent brings a late-stage lung cancer pipeline, reinforcing investor confidence that the transaction is real and financially significant. WSJ article on GSK deal
• Neutral Sentiment: Several law firms have launched investigations into whether the sale process and $124.00 price are fair to shareholders, which could create some headline noise but does not change the announced deal terms yet. Business Wire article on investigation
• Neutral Sentiment: Wells Fargo and other brokers trimmed ratings after the takeover announcement, but their updated price targets remain near the deal value, so these moves are unlikely to outweigh the acquisition news. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly pressure sentiment by reinforcing that insiders have been reducing exposure ahead of the transaction. SEC insider filing

Institutional Investors Weigh In On Nuvalent

A number of institutional investors and hedge funds have recently bought and sold shares of NUVL. GAMMA Investing LLC raised its stake in Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after purchasing an additional 108 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Nuvalent by 141.3% in the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after purchasing an additional 195 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Nuvalent in the third quarter valued at approximately $38,000. NBC Securities Inc. purchased a new stake in Nuvalent in the fourth quarter valued at approximately $125,000. Finally, KBC Group NV raised its stake in Nuvalent by 24.1% in the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after purchasing an additional 297 shares in the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.